PolyPid’s Promising Future: Buy Rating Backed by D-PLEX100 Progress and Expanding Drug Delivery Pipeline
Analyst Brandon Folkes of H.C. Wainwright has reiterated a Buy rating on PolyPid, maintaining a price target of $13.00. This rating is supported by the promising progress of D-PLEX100, which is set for NDA submission in early 2026 after positive Phase 3 trial results. The product shows significant efficacy in reducing surgical site infections. Additionally, PolyPid is expanding its drug delivery technology, with potential new products targeting obesity and diabetes. The company’s strong operational performance and favorable market cap of $60M enhance its risk-reward profile.
Analyst Brandon Folkes of H.C. Wainwright reiterated a Buy rating on PolyPid, retaining the price target of $13.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Brandon Folkes has given his Buy rating due to a combination of factors that highlight PolyPid’s promising future. The company has made significant progress with its D-PLEX100 product, which is on track for an NDA submission in early 2026 following positive Phase 3 trial results. This product demonstrated a substantial reduction in surgical site infections, showcasing its efficacy and safety.
Beyond D-PLEX100, PolyPid is advancing its drug delivery technology, which has the potential to expand into a pipeline of products, including a long-acting GLP-1 delivery platform targeting obesity and diabetes. The company’s successful regulatory inspections and ongoing U.S. partnership discussions further validate its operational strength. With a market cap of $60M, PolyPid offers a favorable risk-reward profile, supported by its cash reserves projected to fund operations well into 2026.
